Targeting Soluble Guanylyl Cyclase during Ischemia and Reperfusion [PDF]
Cells, 2023 Ischemia and reperfusion (IR) damage organs and contribute to many disease states. Few effective treatments exist that attenuate IR injury. The augmentation of nitric oxide (NO) signaling remains a promising therapeutic target for IR injury.
Eric H. Mace +3 more
doaj +4 more sources
Effects of soluble guanylyl cyclase stimulation on muscle oxygenation and exercise capacity in heart failure with mildly reduced ejection fraction [PDF]
Experimental PhysiologyHeart failure (HF) with a mildly reduced ejection fraction (HFmrEF; 40%–49%) is present in ≤25% of HF patients. Therapeutic treatment options for HFmrEF‐associated exercise intolerance are limited.
Ramona E. Weber +10 more
doaj +3 more sources
Soluble guanylyl cyclase mediates noncanonical nitric oxide signaling by nitrosothiol transfer under oxidative stress [PDF]
Redox Biology, 2022 Soluble guanylyl cyclase (GC1) is an α/β heterodimer producing cGMP when stimulated by nitric oxide (NO). The NO-GC1-cGMP pathway is essential for cardiovascular homeostasis but is disrupted by oxidative stress, which causes GC1 desensitization to NO by ...
Chuanlong Cui +5 more
doaj +3 more sources
Soluble Guanylyl Cyclase Activators—Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension [PDF]
Molecules, 2023 Endogenous nitric oxide (NO)-dependent vascular relaxation plays a leading role in the homeostasis of the cardiovascular, pulmonary, and vascular systems and organs, such as the kidneys, brain, and liver.
Grzegorz Grześk +6 more
doaj +2 more sources
Stimulation of Erythrocyte Soluble Guanylyl Cyclase Induces cGMP Export and Cardioprotection in Type 2 Diabetes [PDF]
JACC: Basic to Translational Science, 2023 Summary: Reduced nitric oxide (NO) bioactivity in red blood cells (RBCs) is critical for augmented myocardial ischemia-reperfusion injury in type 2 diabetes.
Tong Jiao, MD, PhD +10 more
doaj +2 more sources
The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy. [PDF]
PLoS ONE, 2012 Although evidence now suggests cGMP is a negative regulator of cardiac hypertrophy, the direct consequences of the soluble guanylyl cyclase (sGC) activator BAY 58-2667 on cardiac remodeling, independent of changes in hemodynamic load, has not been ...
Jennifer C Irvine +7 more
doaj +3 more sources
Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation. [PDF]
PLoS ONE, 2012 New therapeutic targets for cardiac hypertrophy, an independent risk factor for heart failure and death, are essential. HNO is a novel redox sibling of NO• attracting considerable attention for the treatment of cardiovascular disorders, eliciting cGMP ...
Eliane Q Lin +9 more
doaj +3 more sources
Soluble guanylyl cyclase: Molecular basis for ligand selectivity and action in vitro and in vivo [PDF]
Frontiers in Molecular Biosciences, 2022 Nitric oxide (NO), carbon monoxide (CO), oxygen (O2), hydrogen sulfide (H2S) are gaseous molecules that play important roles in the physiology and pathophysiology of eukaryotes.
Gang Wu, Iraida Sharina, Emil Martin
doaj +2 more sources
Cellular Factors That Shape the Activity or Function of Nitric Oxide-Stimulated Soluble Guanylyl Cyclase [PDF]
Cells, 2023 NO-stimulated guanylyl cyclase (SGC) is a hemoprotein that plays key roles in various physiological functions. SGC is a typical enzyme-linked receptor that combines the functions of a sensor for NO gas and cGMP generator.
Iraida Sharina, Emil Martin
doaj +2 more sources
Inhibitory Peptide of Soluble Guanylyl Cyclase/Trx1 Interface Blunts the Dual Redox Signaling Functions of the Complex [PDF]
Antioxidants, 2023 Soluble guanylyl cyclase (GC1) and oxido-reductase thioredoxin (Trx1) form a complex that mediates two NO signaling pathways as a function of the redox state of cells.
Chuanlong Cui +5 more
doaj +2 more sources